NISA INVESTMENT ADVISORS, LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.

Quarter-by-quarter ownership
NISA INVESTMENT ADVISORS, LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$230,342
-81.5%
4,422
-77.5%
0.00%
-77.8%
Q2 2023$1,242,465
+515445.6%
19,622
+341.7%
0.01%
+350.0%
Q1 2023$241
+2.1%
4,442
-0.4%
0.00%0.0%
Q4 2022$236
-99.9%
4,4620.0%0.00%0.0%
Q3 2022$205,000
-12.4%
4,462
+9.1%
0.00%0.0%
Q2 2022$234,000
-17.0%
4,091
-11.3%
0.00%0.0%
Q1 2022$282,000
-33.0%
4,611
-48.0%
0.00%
-33.3%
Q4 2021$421,000
+28.0%
8,869
+0.5%
0.00%
+50.0%
Q3 2021$329,000
-7.3%
8,822
+1.4%
0.00%0.0%
Q2 2021$355,000
+20.3%
8,7000.0%0.00%0.0%
Q1 2021$295,000
+6.5%
8,7000.0%0.00%0.0%
Q4 2020$277,000
+44.3%
8,700
+16.4%
0.00%0.0%
Q3 2020$192,000
-27.5%
7,475
-27.6%
0.00%0.0%
Q2 2020$265,000
+75.5%
10,322
+4.8%
0.00%0.0%
Q1 2020$151,000
-53.1%
9,850
+5.0%
0.00%
-33.3%
Q4 2019$322,000
+360.0%
9,3800.0%0.00%
+200.0%
Q3 2019$70,000
+775.0%
9,380
+1776.0%
0.00%
Q3 2016$8,000
-57.9%
5000.0%0.00%
Q2 2016$19,000
+35.7%
5000.0%0.00%
Q1 2016$14,0005000.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q1 2023
NameSharesValueWeighting ↓
DCF Advisers, LLC 359,000$18,790,0007.62%
Velan Capital Investment Management LP 150,000$7,851,0006.09%
SILVERARC CAPITAL MANAGEMENT, LLC 195,000$10,206,0004.14%
Vantage Consulting Group Inc 226,670$11,864,0003.19%
Vahanian & Associates Financial Planning Inc. 71,742$3,755,0003.03%
Nicholas Investment Partners, LP 652,886$34,172,0002.16%
COOPER/HAIMS ADVISORS, LLC 61,116$3,199,0001.97%
Bellevue Group AG 3,628,919$189,938,0001.96%
WASATCH ADVISORS LP 8,235,171$431,029,0001.76%
Quantum Private Wealth, LLC 77,622$4,062,0001.54%
View complete list of INTRA CELLULAR THERAPIES INC shareholders